- TLDR Biotech
- Archive
- Page 11
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | September 30 - October 1, 2024
Kailera launches with $400M and big obesity dreams, Biohaven’s $250M public offering, SK pharmteco drops $260M for new manufacturing site, Zephyrm Bioscience files for Hong Kong stock exchange IPO, BioMarin signs RNA R&D deal with CAMP4, FDA and FTC both urged by US senators to do more (in different ways), J&J, Bayer, Pfizer all post new layoffs (totally 500 jobs), Gritstone bio considers the dreaded “strategic alternatives” as cash pile dwindles, Amgen casually forgets to mention $10.7B in back taxes to investors; class-action suit ensues
Biotech & Pharma Updates | September 29 - 30, 2024
Roche pays $850M upfront for Regor Pharma’s breast cancer assets, Eli Lilly’s thyroid cancer med lands full FDA approval, J&J scores two Ph3 wins in multiple myeloma, DCVC Bio closes oversubscribed $400M fund, BMS & Celgene shareholder suit dismissed by NY federal judge, Prime slashes pipeline and signs up to $3.5B drug development pact with BMS, J&J pauses 340B rebate program roll-out after increased HRSA pressure, Ensoma closes Copenhagen site, Otsuka and Moderna both commit serious marketing faux pas according to UK’s pharma marketing watchdog
Biotech & Pharma Updates | September 26 - 29, 2024
Regeneron, Sanofi’s Dupixent gets FDA ok for label expansion, Bavarian Nordic lands another mpox vaccine contract, BlueRock, Bayer showcase 24 month safety data for Parkinson’s disease cell therapy, Cassava’s $40M SEC settlement, Travere halts Ph3 due to drug substance issue, J&J gets final warning letter from HRSA to halt 340B rebate program
Biotech & Pharma Updates | September 25 - 26, 2024
BMS’s historic schizophrenia FDA approval, ARCH Venture Partners $3B 13th fund, Genentech touts positive Ph3 Gazyva lupus data, CSL Seqirus nabs another BARDA bird flu contract, Mirai Bio launches as Flagship’s newest endeavour, Novo Nordisk & Evotec partner to develop off-the-shelf stem-cell derived cell therapies, Inventiva’s coffers are weeks from running dry, Biogen and Sage discontinue essential tremor partnership, FDA adcomm advises narrower PD-1 inhibitor approvals, top NIH neuroscientist conducted alleged widespread Parkinson’s & Alzheimer's research misconduct
Biotech & Pharma Updates | September 24 - 25, 2024
Emergent raking in $400M in mpox, smallpox vaccine orders, Vertex’s Casgevy approved in Canada, Amgen notches mixed wins in atopic dermatitis and myasthenia graves, Genespire’s $52M Series B, Eurofins to build new $64M biologics site, AskBio’s gene therapy collab with Belief BioMed, semaglutide continues wonder-drug tirade with studies pointing to treating a chronic skin condition and opioid use disorder, 2seventy bio & BMS shutter Abecma myeloma trial, J&J allegedly slashing cardiovascular and metabolic disease divisions, Pfizer’s global recall of Oxbryta sickle cell med due to patient deaths
Biotech & Pharma Updates | September 23 - 24, 2024
Novartis’ $1B+ biobucks deal with Generate:Biomedicines, Capricor stock explodes on cell therapy BLA filing intention, Biogen & UCB's two decade lupus struggle seemingly vindicated with a Ph3 win, Constructive Bio’s $58M Series A for cellular bio factories, cell therapy CDMO Minaris to be acquired by investment firm Altaris, Lonza signs on to manufacture Vertex’s Casgevy CRISPR-based therapy, bluebird and AGC both announces layoffs, Baltimore sues Biogen over alleged PBM “bribes” to stifle MS generic competition
Biotech & Pharma Updates | September 22 - 23, 2024
Sanofi scores first-line multiple myeloma approval, Sanofi buys Ventyx's Parkinson’s, obesity asset for $27M, Teva’s once-monthly schizophrenia med hits safety and efficacy endpoints, ViceBio’s $100M raise for next-gen respiratory illness vaccines, CAMP4 goes for $75M IPO, Telix acquires RLS Radiopharmacies, AstraZeneca & Daiichi’s breast cancer ADC stumbles in Ph3, J&J raises Talc settlement offer to $8B
Biotech & Pharma Updates | September 19 - 22, 2024
FTC sues big three pharmacy benefit managers over insulin prices, AstraZeneca’s (MedImmune) nasal spray flu vaccine scores FDA approval, J&J adds third Rybrevant lung cancer indication, Gilead contracts Yuhan corp for HIV drug ingredient manufacturing, FDA site inspectors hiring ongoing to combat inspection backlog, Novo’s CB1 obesity med takes Ph2 hit over neuropsychiatric side effects, BMS to cut 79 New Jersey-based staffers, Monkey outbreak rages on in Africa
Biotech & Pharma Updates | September 18 - 19, 2024
GC Therapeutics launches with $75M to revolutionize cell therapy, Roche’s positive antiviral Ph3 data, Tanai Therapeutics’ obesity endeavours further fuelled by Novo Nordisk, Upstream Bio files for IPO, Basilea extends BARDA partnership, Vanda’s gastroparesis small molecule rejected by FDA, biotech small-cap market goes “meh” on US Fed rate cut, Achilles axes TIL-based therapy program, study finds new-gen migraine meds not much better than OTC regulars (eg. tylenol, aspirin)
Biotech & Pharma Updates | September 17 - 18, 2024
Novo Nordisk’s $600M biobucks deal with NanoVation Therapeutics, Roivant sells derm division to Organon, Merck’s Keytruda nabs another indication, BMS and Novartis both boast long term MS data, Brenus Pharma $25M Series A for cancer vaccines, Insilico Medicines' dubious clinical efficacy data, Guardant Health CEO calls cap on Exact Science’s blood-based colon cancer test, Novo Nordisk accused of excessive Ozempic price gouging
Biotech & Pharma Updates | September 16 - 17, 2024
Novartis nabs Kisqali label expansion, AC Immune lands $29M Alzheimer’s milestone payment, Merck & Daiichi’s ADC bests chemo in lung cancer Ph3, Cape Fear BioCapital’s new early-stage therapeutic seed fund, Sandoz wins against United Therapeutics in yearslong generics spat, AbbVie & Ripple RTC-620 development partnership, Athira lays off 70%, biopharma mulls advancing Biosecure act, Express Scripts sues FTC over “biased” report
Biotech & Pharma Updates | September 14 - 16, 2024
Novo Nordisk & Korro Bio sign $530M biobucks pact, Eli Lilly nabs FDA eczema approval, Pfizer posts positive cancer cachexia Ph2 data, BMS' impressive 10+ year survival in Ph3 melanoma trial, Nuvalent’s proposed $500M public offering, mRNA COVID-19 vaccines may increase cancer immunotherapy effectiveness, Intercept’s Ocaliva faces FDA adcomm ire, BMS walks from $150M Immatics bispecific wager